GAMMA Investing
SPRY icon

GAMMA Investing’s ARS Pharmaceuticals SPRY Stock Holding History

GAMMA Investing’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.48K Sell
808
-448
-36% -$2.62K ﹤0.01% 3785
2026
Q2 		$10.1K Buy
1,256
+653
+108% +$5.62K ﹤0.01% 3200
2026
Q1 		$4.84K Buy
603
+495
+458% +$4.74K ﹤0.01% 3372
2025
Q4 		$1.26K Sell
108
-71
-40% -$690 ﹤0.01% 3729
2025
Q3 		$1.8K Sell
179
-116
-39% -$1.66K ﹤0.01% 3476
2025
Q2 		$5.15K Buy
295
+28
+10% +$404 ﹤0.01% 3104
2025
Q1 		$3.36K Buy
267
+191
+251% +$2.3K ﹤0.01% 3236
2024
Q4 		$802 Sell
76
-31
-29% -$434 ﹤0.01% 3476
2024
Q3 		$1.55K Buy
107
+31
+41% +$369 ﹤0.01% 3140
2024
Q2 		$647 Sell
76
-24
-24% -$213 ﹤0.01% 3155
2024
Q1 		$1.02K Buy
100
+24
+32% +$179 ﹤0.01% 2937
2023
Q4 		$472 Buy
+76
New +$333 ﹤0.01% 2980

Other funds holding SPRY

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
NFGCM
Norman Fields Gottscho Capital Management New York $329M AUM 22.06% 1-Year Est. Return
CX Institutional
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
BLC
Brown, Lisle/Cummings Providence, Rhode Island $453M AUM 20.23% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

GAMMA Investing's SPRY Position: Q3 2026 in Review

GAMMA Investing reduced its ARS Pharmaceuticals (SPRY) stake by 36% in Q3 2026, selling an estimated $2.62K and leaving 808 shares worth $3.48K. The position accounts for ﹤0.01% of the portfolio, ranked #3785.

GAMMA Investing first reported a position in SPRY in Q4 2023 and has held it in 12 quarters since. The position peaked at $10.1K in Q2 2026. 12 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • GAMMA Investing held 808 shares of ARS Pharmaceuticals worth $3.48K as of Q3 2026.
  • GAMMA Investing sold 448 ARS Pharmaceuticals shares in Q3 2026, an estimated $2.62K.
  • ARS Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3785 holding.
  • GAMMA Investing first reported a position in ARS Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's ARS Pharmaceuticals position peaked at $10.1K in Q2 2026.
  • 12 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.